Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults-a systematic review and meta-analysis

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 2, 2015, Pages 179-188

  Holtick, Udo ^a   Albrecht, Melanie ^a   Chemnitz, Jens M ^a   Theurich, Sebastian ^a   Shimabukuro Vornhagen, Alexander ^a   Skoetz, Nicole ^a   Scheid, Christof ^a   von Bergwelt Baildon, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Allogeneic stem cell transplantation; Bone marrow; Graft versus host disease; Peripheral blood; Stem cell source

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; PREDNISONE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER RECURRENCE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; ENGRAFTMENT; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; META ANALYSIS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE; TREATMENT OUTCOME; ADULT; ADVERSE EFFECTS; AGE; ALLOTRANSPLANTATION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL; MORTALITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE;

ADULT; AGE FACTORS; BLOOD PLATELETS; BONE MARROW TRANSPLANTATION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS; NEUTROPHILS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84926092582     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.12.007     Document Type: Review

References (44)

1. Gratwohl A., Baldomero H., Horisberger B., Schmid C., Passweg J., Urbano-Ispizua A. Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002, 100(7):2374-2386.
2. Anasetti C., Logan B.R., Lee S.J., Waller E.K., Weisdorf D.J., Wingard, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012, 367(16):1487-1496.
3. Bensinger W.I., Martin P.J., Storer B., Clift R., Forman S.J., Negrin R., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001, 344(3):175-181.
4. Blaise D KMFCBJHMNSLJJPAMBPCJ. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol. 2000;18(3):537-46.
5. Champlin R.E., Schmitz N., Horowitz M.M., Chapuis B., Chopra R., Cornelissen J.J., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR histocompatibility and stem cell sources working committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000, 95(12):3702-3709.
6. Cornelissen Jj vdHBPEJVLRCAHMMJSHCB. A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Exp Hematol 2003;31(10):855-64.
7. Couban S., Simpson D.R., Barnett M.J., Bredeson C., Hubesch L., Howson-Jan K., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002, 100(5):1525-1531.
8. Didier Blaise, Mathieu Keuntz, Cecile Fortanier, Jean Henri Bourhis, Noel Milpied, Laurent Sutton, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol 2000, 18(3):537-546.
9. Eapen M., Logan B.R., Confer D.L., Haagenson M., Wagner J.E., Weisdorf D.J., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007, 13(12):1461-1468.
10. Flowers M.E.D., Parker P.M., Johnston L.J., Matos A.V.B., Storer B., Bensinger Wi, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002, 100(2):415-419.
11. Friedrichs B., Tichelli A., Bacigalupo A., Russell N.H., Ruutu T., Shapira My, et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010, 11(4):331-338.
12. Gallardo D., de la Camara R., Nieto J.B., Espigado I., Iriondo A., Jimenez-Velasco A., et al. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study. Haematologica 2009 Sep, 94(9):1282-1288.
13. Heldal D., Brinch L., Tjonnfjord G., Solheim B.G., Egeland T., Albrechtsen D., et al. Fewer relapses and increased chronic GVHD in patients transplanted with blood stem cells: a 5-year follow-up in a single centre study. Bone Marrow Transplant 2003, 32(3):257-264.
14. Mahmoud H., Fahmy O., Kamel A., Kamel M., El-Haddad A., El-Kadi D. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999, 24(4):355-358.
15. Mark Kirschbaum, O'Donnell M, Spielberger R, Bhatia R, Pullarkat V, Stein A, et al. Peripheral blood stem cells vs bone marrow for matched sibling transplant in AML and ALL remission. Blood.104(11 abstract 3321).
16. Mielcarek M, Storer B, Martin PJ, Forman SJ, Negrin RS, Flowers ME, et al. Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear versus bone marrow. Blood 119:2675-8.
17. Mohty M., Kuentz M., Michallet M., Bourhis J.H., Milpied N., Sutton L., et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002, 100(9):3128-3134.
18. Nagafuji K., Matsuo K., Teshima T., Mori S., Sakamaki H., Hidaka M., et al. Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan society for hematopoietic stem cell transplantation registry. Int J Hematol 2010 Jun, 91(5):855-864.
19. Oehler V.G., Radich J.P., Storer B., Blume K.G., Chauncey T., Clift R., et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 2005, 11(2):85-92.
20. Powles R., Mehta J., Kulkarni S., Treleaven J., Millar B., Marsden J., et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000, 355(9211):1231-1237.
21. Ringden O., Labopin M., Bacigalupo A., Arcese W., Schaefer U.W., Willemze R., et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002, 20(24):4655-4664.
22. Ringden O., Labopin M., Beelen D.W., Volin L., Ehninger G., Finke J., et al. Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an acute leukaemia working party analysis in 2262 patients. J Intern Med 2012 Nov, 272(5):472-483.
23. Schmitz N. BMBARTNAGERNAJSJBKBA. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica 2005, 90(5):643-648.
24. Schmitz N., Eapen M., Horowitz M.M., Zhang M.J., Klein J.P., Rizzo J.D., et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the international bone marrow transplant registry and the European group for blood and marrow transplantation. Blood 2006 Dec 15, 108(13):4288-4290.
25. Vigorito A.C., Azevedo W.M., Marques J.F., Azevedo A.M., Eid K.A., Aranha Fj, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998, 22(12):1145-1151.
26. Vigorito A.C., Marques Junior J.F., Aranha F.J., Oliveira G.B., Miranda E.C., De Souza C.A. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: an update. Haematologica 2001, 86(6):665-666.
27. Chang Y.J., Weng C.L., Sun L.X., Zhao Y.T. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials. Ann Hematol 2012, 91(3):427-437.
28. Stem Cell Trialists' Collaborative Croup. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematological malignancies: an individual patient data meta-analysis of nine randomised trials. J Clin Oncol 2005;23:5074-87.
29. Gratwohl A., Baldomero H., Gratwohl M., Aljurf M., Bouzas L.F., Horowitz M., et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a global observational study. Haematologica 2013, 98(8):1282-1290.
30. Gratwohl A., Baldomero H., Schwendener A., Rocha V., Apperley J.F.K., Frauendorfer K., et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009, 43:275-291.
31. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides.〈http://www.cibmtr.org.〉 2013.
32. Pidala J., Anasetti C., Kharfan-Dabaja M.A., Cutler C., Sheldon A., Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15(11):1415-1421.
33. Bensinger W.I. Allogeneic transplantation: peripheral blood vs. bone marrow. Curr Opin Oncol 2012, 24(2):191-196.
34. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyzes of the published literature for survival endpoints. Stat Med 1998, 17(24):2815-2834.
35. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
36. Appelbaum F.R. Hematopoietic-cell transplantation at 50. N Engl J Med 2007, 357(15):1472-1475.
37. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373(9674):1550-1561.
38. Abrahamson I.W., Somme S., Heldal D., Egeland T., Kvale D., Tjonnfjord G.E. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease. Haematologica 2005, 90(1):86-93.
39. Cao T.M., Shizuru J.A., Wong R.M., Sheehan K., Laport G.G., Stockerl-Goldstein K.E., et al. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood 2005, 105(6):2300-2306.
40. Hassan H.T., Stockschlader M., Schleimer B., Kruger W., Zander A.R. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors. Transpl Immunol 1996, 4(4):319-323.
41. Panse J.P., Heimfeld S., Guthrie K.A., Maris M.B., Maloney D.G., Baril B.B., et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol 2005, 128(5):659-667.
42. Nagler A., Labopin M., Shimoni A., Niederwieser D., Mufti G.J., Zander A.R., et al. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the acute leukemia working party of the european group for blood and marrow transplantation. Biol Blood Marrow Transplant 2012, 18(9):1422-1429.
43. De Souza C.A., Durães M.I., Vigorito A.C., Penteado Aranha F.J., Oliveira G.B., De Brito, et al. Quality of life in patients randomized to receive a bone marrow or a peripheral blood allograft. Haematologica 2002, 87:1281-1285.
44. Norkin M., Hsu J.W., Wingard J.R. Quality of life, social challenges, and psychosocial support for long-term survivors after allogeneic hematopoietic stem-cell transplantation. Semin Hematol 2012, 49(1):104-109.